Entrepreneurs Boldly Break New Ground
By Clare Kittredge
Early-stage funding is oxygen to young life science companies struggling to keep their companies afloat and research moving forward.
ACUREON PHARMACEUTICALS - It's all in their heads

Matthew Gantz, CEO of Acureon Pharmaceuticals, says his company's technology is all "in our heads." That's because he and his partner are searching for late-stage therapeutics in the areas of infections, transplants, and critical care to improve for use in hospitals.

"We do not actually have a product; we are looking for one," says Gantz. "We look everywhere - databases, products approved outside the US but not here, serious unmet needs.... The challenge...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?